Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Yildiz Ibrahim, Sen Fatma, Kilic Leyla, Ciftci Rumeysa, Basaran Mert,
소속 상세정보
( Yildiz Ibrahim )
Istanbul University Department of Medical Oncology
( Sen Fatma )
Istanbul University Department of Medical Oncology
( Kilic Leyla )
Istanbul University Department of Medical Oncology
( Ciftci Rumeysa )
Istanbul University Department of Medical Oncology
( Basaran Mert )
Istanbul University Department of Medical Oncology
KMID : 0358320140550010074
Abstract
Sunitinib is a multiple tyrosine kinase receptor inhibitor that is approved for the treatment of metastatic renal cell carcinoma (RCC). However, neither an appropriate dose nor dosing schedule of sunitinib has yet been established for patients with metastatic RCC who are on hemodialysis. Here, we report on two hemodialysis patients who received sunitinib to treat metastatic RCC. Sunitinib was planned to be administered at a dosage of 25 mg/d for 4 of every 6 weeks. Although sunitinib toxicity was manageable in one patient, disease progression occurred after 4 months of treatment. In the second patient, acute pulmonary edema, caused by uncontrolled hypertension, developed on the 15th day of sunitinib therapy and the drug had to be discontinued. Sunitinib is thus not well tolerated in a hemodialysis setting. Close monitoring of toxicity and dose manipulation may be required if such therapy is attempted
키워드
Renal cell carcinoma; Renal dialysis; Sunitinib
원문 및 링크아웃 정보
등재저널 정보